The use of ureteral stents after kidney transplantation (KTx) remains controversial. Methods: We reviewed urologic complications in 288 (83 cadaver {CAD}, 205 living related donor {LRD}), primary adult KTx performed at the University of Illinois at Chicago, between 1/02 and 1/06. The ureteral anastomosis consisted of a standardized ureteroneocystostomy according to the Lich technique. Double J (JJ), stents were placed across the anastomosis in 209 patients (Group A), and were not used in the remaining 79 patients (Group B). Stents were removed cystoscopically after 30 days. Immunosuppression consisted of Thymoglobulin induction and maintenance with Mycophenolate Mofetil (MMF) and Tacrolimus (TAC); steroids were discontinued on post-op day (POD) 6. The incidence of urinary tract infection treated on an out-patient basis (UTI/OP-TX) or requiring hospitalization (UTI/HTX) during the first three months, hematuria, urinary leak and obstruction were recorded. A cost analysis was performed. Results: There was no difference in the incidence of UTI/HTX between the two groups. While not statistically significant, there was a trend toward a higher incidence of UTI/OPTX in the stent group (p=0.052). Furthermore, females in the stent group had a significantly higher incidence of UTI/OPTX (N=20, 10%) (p=0.002), and a significantly higher rate of UTI/HTX (N=9, 4%) (p=0.031). There was no significant difference in the rate of gross hematuria in the two groups. While there were no urologic complications in the stent group, one patient (1.3%), in the unstented group developed urinary obstruction due to stricture at the pyelo-ureteral junction, successfully treated by percutaneous stenting. Patient cost related to the use of stents was $1800.00. Conclusion: Routine use of stents may not be indicated after KTX since this practice did not significantly affect the rate of urologic complications and is associated with an increased incidence of UTI in females as well as increased patient costs. 
Introduction
In the past, urologic complications after kidney transplantation (KTx) have been a common cause of technical failure contributing to significant morbidity and mortality. The majority of these complications are related to the ureteral-vesicular anastomosis (1, 2) . While early reports site a 20-29% incidence of ureteral complications (3), improvements in surgical techniques have lowered the current incidence to 5-10% (2, 4) . The use of ureteral stents after KTx, remains controversial. Studies support the use of stents to lower the risk of some urologic complications. These benefits include decreased incidence of obstruction, urine leak and fluid collection. No subsequent increase in incidence of UTI was noted (1, 5, 6) . Others have produced conflicting results (7, 8) and advocate the use of selective stenting for KTx recipients (7, 9) . This retrospective data analysis was done to study the effect of Double J (JJ) stents on the complication rate of adult primary KTx recipients in our patient population.
Materials and Methods
We retrospectively reviewed the urological complications of adult primary KTx recipients transplanted at the University of Illinois Medical Center, Chicago, between January 2002 and January 2006. A total of 288 consecutive cases (83 CAD, 205 LRD), were reviewed. Ureteral anastomosis consisted of a standardized uretero-neocystostomy as described by Lich. JJ stents (4.5 Fr) were placed across the anastomosis in 209 patients (Group A), and were not used in the remaining 79 patients (Group B). Stents were removed cystoscopically after 30 days using local anesthesia. An indwelling urethral catheter was maintained 5 days posttransplant. Induction therapy was the same for both groups and consisted of Thymoglobulin, 1.5mg/kg IVPB on post-operative days (POD) 0 through 5. Methylprednisolone 500mg IVPB was given over 30 minutes intra-operatively. All patients received Prednisone 1mg/kg/day on POD #1; 0.5mg/kg/day on POD #2 and 3; 0.25mg/kg/day on POD #4 and #5. All steroids were stopped on POD #6. Maintenance immunosuppression Abbreviations cadaver -CAD Double J -JJ Hospitalization -HTX kidney transplantation -KTx living related donor -LRD consisted of Mycophenolate Mofetil (MMF), 1 GM BID and Tacrolimus (TAC) 0.1mg/kg/day, adjusted to achieve through levels of 8-12ng/ml for 2 months then 5-10ng/ml. Living related recipients received Ancef 1GM IVPB prior to transplant, while cadaver recipients received Ancef 1GM IVPB prior to transplant and on POD #1 and 2. All recipients received Bactrim 400/80 daily for 6 months as prophylaxis against urinary tract infections (UTI) and Pneumocystis Carini pneumonia. All recipients were monitored routinely with serum creatinine, BUN, leukocyte count, urinalysis and urine culture. Episodes of renal dysfunction were investigated as clinically indicated. One year serum creatinine, patient and graft survival were recorded. Study endpoints compared in the two groups included UTI/OPTX, UTI/HTX, hematuria, urinary leak and obstruction. A cost analysis was performed. UTI/OPTX was defined as a positive urine culture with pyuria. UTI/HTX was indicated when positive urine culture with pyuria was accompanied by fever > 102, chills, hypotension or increased serum creatinine. Episodes of hematuria requiring cystoscopy for evaluation were recorded. Urinary leak was suspected clinically and defined as drainage or accumulation of peri-renal fluid with the characteristics of urine. Obstruction was assessed by ultrasound or renal scan and confirmed by nephrostogram. Data was entered into a Microsoft (Excel) database and queried as appropriate for means +/-. Means were compared by Student-t test for continuous data. Variables were compared using a Pearson Chi-square analysis. P values of (0.05) were statistically significant.
Results
Demographics 288 primary adult KTx recipients were included in the study. Table 1 summarized the characteristics of the patient population. 209 recipients Group (A) had JJ stents placed across the anastomosis. The remaining 79 recipients Group (B) were transplanted without the use of stents. There were no statistically significant differences in age, gender, racial distribution or donor source in the two groups.
Patient/Graft Survival
Patient survival was 98% for Group A, compared to 95% for Group B. Graft survival for Group A was 98% compared to 94% in Group B, which was not statistically significant. At 1 year, mean serum creatinine in Group A was 1.7, compared to 1.6 for Group B. No significant increase of creatinine was noted in either group during the 1 st post transplant year. There was no graft loss or mortality related to urological complications in either group.
Infection/Hematuria
Overall, there was no difference in the incidence of UTI /HTX between the two groups. The rate of hospitalization for Group A was (N=12, 6%) compared to Group B (N=2, 3%). While not statistically significant, overall, there was a trend toward a higher incidence of UTI/OPTX in the stent group (N=28, 13%), compared to the unstented group (N=18, 23%) (p=0.052). In the stent group, UTI/OPTX occurred within the first three months post-transplant while in the unstented group UTI/OPTX oc- Figure 1 curred after the first 6 months. Causative organisms were similar in both groups (Figure 1 ). Females in the stent Group (A), had a statistically significant higher incidence of UTI/OPTX (N=20, 10%), compared to males in Group A (N=8, 4%) (p=0.002), and a statistically significant higher rate of UTI/HTX (N=9, 4%), compared to males in Group A (N=3, 1%) (p=0.031). The incidence of hematuria was not significantly different in the two groups. These findings are summarized in table 2.
Obstruction/Leak
No cases of urinary leak occurred in either group. Although there were no urologic complications in the stent group (N=209), on POD # 45, one recipient in the unstented group (N=79) (1.3%), developed urinary obstruction due to stricture at the pyelo-ureteral junction which was successfully treated with percutaneous stenting. The following minor stent related problems were identified: 1 stent was removed on POD# 14 due to recurrent UTI, 3 stents were retained due to patient noncompliance with follow-up. Additional cost per patient related to the use of stents was $1800.00, which includes the cost of materials, cystoscopic removal and abdominal x-ray.
Discussion
Although the overall rate of stent related complications has decreased over the last 30 years, routine use of ureteral stents remains controversial. Studies report complication rates as high as 13% in unstented KTx recipients (6) . Some suggest routine use of stents lowers this rate to less than 8% (1, 5, 6) . Other trials could not identify an advantage to routine stenting (8) and conclude that selective stenting yields complication rates similar to those seen when stents are used routinely (7, 9) . We studied the effect of JJ stents on the complication rates of adult, primary KTx recipients. In our study, the overall rate of urologic complications in both groups was 5%. This finding is lower than the 13% reported for unstented patients in previous trials (6) , and comparable to the 5% complication rate reported for patients selectively stented (7). While we found no cases of urinary leak, 1 case (1.3%), of urinary obstruction due to stricture at the pyelo-ureteral junction was reported. No permanent dysfunction or graft loss was observed. Several factors may explain the low incidence of urologic complications found in our study. Surgical skill and techniques using shorter ureters and minimal bladder incisions has been found to lower the rate of urologic complications from 9.4 to 3.7% (10) . Individualized immunosuppression and steroid minimization may facilitate wound healing and promote optimal organ function. Furthermore, the use of various radiological procedures and percutaneous techniques has allowed for early diagnosis and non-invasive treatments (11, 12) . Frequency of UTI related to the use of JJ stents has also been studied. Although severe infections have been reported (5), with a rate of UTI as high as 31% (8), most studies report no significant difference in the rate of UTI between stented and unstented patients (1, 5) . Similarly, in our study, the rate of UTI in stented patients was 23%.
Although there was a trend toward a higher incidence of UTI/OPTX within the first 3 months post-transplant, we found no difference in the incidence of UTI/HTX in the two groups. Importantly, there was a significantly higher rate of UTI/OPTX and UTI/HTX among stented female patients. While not documented in previous studies, this finding may be attributed to the increased risk for UTI associated with female gender and may support selective stenting or early stent removal in female patients. Finally, we analyzed the costs involved in the use of routine stents. Additional cost per patient related to the use of JJ stents was 1800.00 U.S. dollars. In other studies, these costs were offset by lower complication rates attributed to stent use (1) . Conversely, the low urologic complication rate found in our study, and high patient costs associated with stent use, would not appear to support routine use of JJ stents in KTx recipients at our center. Although the risk of urological complications following KTx has decreased over the last several years, the controversy regarding the use of ureteral stents continues. At our center, routine use of stents may not be indicated as this practice did not significantly affect the rate of urologic complications and was associated with increased patient costs. Importantly, female gender was associated with a significantly higher rate of UTI and should be considered as a potential risk factor if JJ stents are used. 
